C12N 2501/604
Klf-4
C12N2501/604 (Klf-4) appears on 278 US grants and 566 published applications in this corpus.
Search patents in C12N- Granted patents
- 278
- Published applications
- 566
- Assignees
- 236
- Inventors
- 933
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 10 |
| 2010 | 0 | 26 |
| 2011 | 3 | 38 |
| 2012 | 7 | 41 |
| 2013 | 10 | 46 |
| 2014 | 17 | 34 |
| 2015 | 20 | 33 |
| 2016 | 33 | 41 |
| 2017 | 27 | 50 |
| 2018 | 29 | 39 |
| 2019 | 23 | 30 |
| 2020 | 18 | 31 |
| 2021 | 17 | 36 |
| 2022 | 14 | 25 |
| 2023 | 12 | 23 |
| 2024 | 25 | 27 |
| 2025 | 14 | 24 |
| 2026 | 9 | 11 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Composition for enhancing reprogramming efficiency from somatic cell to induced pluripotent stem cell, comprising mTOR activator, and method for enhancing reprogramming efficiency by using same6 Oct 2026US 12,753,394 B2Korea University Research and Business Foundation
- Immune cells derived from induced pluripotent stem cell14 Jul 2026US 12,680,075 B2Children's Medical Center Corporation
- And efficient method for reprogramming blood to induced pluripotent stem cells14 Jul 2026US 12,680,082 B2Cedars-Sinai Medical Center
- RNA preparations comprising purified modified RNA for reprogramming cells16 Jun 2026US 12,655,395 B2
- Methods for reprogramming cells and uses thereof12 May 2026US 12,624,342 B2Genesis Technologies Limited
- Oct3/4 protein variants, and method for producing induced pluripotent stem cells1 Oct 2026US 2026/0297535 A1Riken
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- System and method for capillary blood stem cell reprogramming using upper-arm blood collection devices for patient-specific disease modeling10 Sep 2026US 2026/0265698 A1TimepointDx
- Method for producing primed pluripotent stem cells27 Aug 2026US 2026/0250631 A1Kyoto University
- Generation of induced pluripotent stem cells with polycistronic sox2, klf4, and optionally c-myc6 Aug 2026US 2026/0226422 A1Beixcell (Beijing) Biotechnology Ltd.
Most cited
By later US patents
- Nuclear reprogramming factor151US 8,048,999 B2Kyoto University · 2011
- Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells126US 9,850,499 B2Loma Linda University · 2017
- Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells125US 8,058,065 B2Kyoto University · 2011
- Compositions and methods for reprogramming eukaryotic cells103US 8,808,982 B2Cellscript, LLC · 2014
- Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox284US 8,129,187 B2Kyoto University · 2012